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T
he burden of cardiovascular disease
(CVD) among patients with diabetes
is substantial. Individuals with diabe-
tes are at two- to fourfold increased risk of
cardiovascular events compared with age-
and sex-matched individuals without dia-
betes.Indiabeticpatientsovertheageof65
years, 68% of deaths are from coronary
heart disease (CHD) and 16% are from
stroke(1).Anumberofmechanismsforthe
increased cardiovascular risk with diabetes
have been proposed, including increased
tendency toward intracoronary thrombus
formation(2),increasedplateletreactivity(3),
and worsened endothelial dysfunction (4).
The increased risk for cardiovascular
events and mortality in patients with dia-
betes has led to considerable interest in
identifying effective means for cardiovas-
cular risk reduction. Aspirin has been
shown to be effective in reducing cardio-
vascular morbidity and mortality in high-
risk patients with myocardial infarction
(MI) or stroke (secondary prevention)
(5). The Food and Drug Administration
has not approved aspirin for use in pri-
mary prevention, and its net beneﬁt
among patients with no previous cardio-
vascular events is more controversial, for
both patients with and without a history
of diabetes (5). The U.S. Preventive Ser-
vices Task Force recently updated its rec-
ommendationaboutaspirinuseforprimary
prevention. The Task Force recommended
encouraging aspirin use in men age 45–79
years and women age 55–79 years and not
encouraging aspirin use in younger adults.
They did not differentiate their recommen-
dationsbasedonthepresenceorabsenceof
diabetes (6,7).
In 2007, the American Diabetes Asso-
ciation (ADA) and the American Heart As-
sociation (AHA) jointly recommended that
aspirintherapy(75–162mg/day)beusedas
a primary prevention strategy in those with
diabetesatincreasedcardiovascularrisk,in-
cluding those who are over 40 years of age
or who have additional risk factors (family
history of CVD, hypertension, smoking,
dyslipidemia, or albuminuria) (8). These
recommendations were derived from sev-
eral older trials that included relatively
smallnumbersofpatientswithdiabetes.Re-
sults of two recent randomized controlled
trialsofaspirinperformedspeciﬁcallyinpa-
tients with diabetes raised questions about
the efﬁcacy of aspirin for primary preven-
tion in diabetes (9,10).
Because of the scope of the problem of
CVD in patients with diabetes and the con-
ﬂicting evidence about the efﬁcacy of aspi-
rin for primary prevention in people with
diabetes, the ADA, AHA, and the American
College of Cardiology Foundation (ACCF)
convened a group of experts to review and
synthesize the available evidence and use
this information to create updated recom-
mendations. The group considered and or-
ganized this report around the following
questions:
1. Whatistheevidenceregardingaspirin
topreventinitialcardiovascularevents
in people with diabetes?
2. Howcanwereconciletheresultsofthe
different primary prevention trials?
3. What are the risks of aspirin, and are
thesesimilarordifferentforpeoplewith
diabetes compared to those without?
4. What do we know about the recom-
mended dosage or dosage range?
5. How can we integrate potential bene-
ﬁts and risks of aspirin to determine
which patients with diabetes should
receiveaspirinfortheprimarypreven-
tion of cardiovascular events?
6. What are the needs for future research?
1. What is the evidence regarding
aspirin to prevent initial
cardiovascular events in people
with diabetes?
Several randomized trials have examined
the effect of aspirin for primary preven-
tion of cardiovascular events and have in-
cludedpatientswithdiabetes(Table1).In
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with respect to the ability of aspirin to
preventcardiovascularevents,whichtyp-
ically include ischemic or CHD events
(MI, sometimes unstable angina), stroke,
and vascular death (usually sudden car-
diac death or death from stroke).
Six trials—British Medical Doctors
(BMD) (11), Physicians’ Health Study
(PHS) (12), Thrombosis Prevention Trial
(TPT) (13), Hypertension Optimal Treat-
ment (HOT) (14), Primary Prevention
Project (PPP) (15,16), and Women’s
Health Study (WHS) (17)—were popula-
tion-based and did not focus speciﬁcally
on patients with diabetes. The percentage
of patients with diabetes in these studies
rangedfrom1–2%inTPT,BMD,andPHS
to 22% in PPP. Two recent trials, the Jap-
anese Primary Prevention of Atheroscle-
rosis with Aspirin for Diabetes (JPAD) (9)
and the Prevention of Progression of Ar-
terial Disease and Diabetes (POPADAD)
(10), and one older trial, the Early Treat-
ment of Diabetic Retinopathy Study
(ETDRS)(18),enrolledonlypatientswith
diabetes. The available trials (except
ETDRS) included mainly or exclusively
patients with type 2 diabetes. ETDRS en-
rolled patients with both type 1 and type
2 diabetes (31% type 1, 31% type 2, and
38% unclassiﬁed).
Threetrials(BMD,PHS,andTPT)did
not include any women, and one (WHS)
focusedsolelyonwomen.Theproportion
of women in the remaining ﬁve trials var-
ied from 44 to 56%. The dose of aspirin
varied from 100 mg every other day to
650 mg daily. The nine trials ranged from
3.7 to 10.1 years in mean duration, with
most extending to 4–6 years. Each of the
trials excluded potential participants at
increased risk of gastrointestinal bleeding
based on a history of peptic ulcer disease.
Therefore, the ﬁndings of this meta-
analysis, which are based on these trials,
cannot be readily extended to patients
withahistoryofgastrointestinalbleeding.
Only two of the nine trials reported
on use of statins or other lipid-lowering
therapy. In JPAD, statin use was 26%,
while in PPP lipid-lowering therapy use
was 13%. Three trials (BMD, PHS, and
ETDRS) were conducted prior to the
availability of statins, and TPT and HOT
were conducted well before the wide-
spread use of statins for primary preven-
tion. Rates of usage in the more recent
POPADAD or WHS trials were not
reported.
The PHS trial enrolled 533 men with
diabetes and found a 41% relative risk
(RR) reduction (RR 0.59, 95% CI 0.33–
1.06)infatalandnonfatalMIover5years
forthoseassignedto325mgaspirinevery
other day compared with those assigned
to placebo (12). The HOT trial examined
the effect of 75 mg of aspirin daily versus
placebo in 18,000 patients ages 50–80
years, of whom 1,501 had diabetes.
Amongthosewithdiabetes,theRRreduc-
tion for CHD events was 23% (RR 0.77,
95% CI 0.44–1.36) (14). The PPP trial
enrolled 1,031 patients with diabetes and
found a nonsigniﬁcant reduction in the
combined MI end point (fatal plus nonfa-
tal MI) with 100 mg of aspirin daily com-
pared with placebo (RR 0.50, 95% CI
0.17–1.46) (15).
The BMD and TPT studies enrolled
relatively few patients with diabetes and
did not identify important reductions in
CVD risk for those with diabetes, but in
each case conﬁdence intervals were quite
wide (11,13). The WHS trial, the only
trial that focused exclusively on women
and used the lowest dose of aspirin (100
mgeveryotherday),didnotﬁndareduc-
tion in risk for CHD with aspirin overall
or for the subset with diabetes (N 
1,027;RR1.34,95%CI0.85–2.12).They
did, however, identify a reduction in
stroke with aspirin for women with dia-
betes (RR 0.45, 95% CI 0.25–0.82) (17).
Three trials focused on the effect of
aspirin exclusively among patients with
diabetes. The ETDRS trial examined the
effect of 650 mg of aspirin daily versus
placeboamong3,711patientswithtype1
ortype2diabetesbetweenages18and70
years who had some degree of retinopa-
thy. Approximately one-half of partici-
pants reported some history of CVD,
although it should be noted that the def-
inition of CVD included the use of anti-
hypertensive medication. Fewer than
10%hadhadapreviousMIorstroke,and
9% had claudication. Intervention pa-
tients experienced a decreased risk of
nonfatal or fatal MI (RR 0.85, 95% CI
0.73–1.00). In contrast, stroke occurred
more frequently with aspirin, although
the difference was not statistically signiﬁ-
cant (RR 1.18, 99% CI 0.88–1.58). Men
appeared to derive more beneﬁt from as-
pirin than women for prevention of MI
(RR for men 0.74, 99% CI 0.54–1.00; RR
for women 0.91, 99% CI 0.65–1.28), but
this difference was not statistically signif-
icant and could represent a chance ﬁnd-
ing (18).
The POPADAD trial studied whether
aspirin and/or antioxidant therapy was
more effective than placebo in reducing
the incidence of cardiovascular events in
patients with diabetes and asymptomatic
peripheral arterial disease. This random-
ized, multicenter, double-blind, placebo-
controlled trial involved 1,276 adults
over age 40 years with either type 1 or
type 2 diabetes. All subjects had an ankle
brachial pressure index less than 0.99 but
no symptomatic CVD. They were ran-
domized in a 22 factorial design to as-
pirin 100 mg daily, an antioxidant
supplement daily, both, or neither. Two
composite primary end points were 1)
deathfromCHDorstroke,nonfatalMIor
stroke, or amputation above the ankle for
critical limb ischemia; and 2) death from
CHD or stroke. Study medication discon-
tinuation rates were high: 14% at 1 year
and 50% at 5 years. Overall, 116 of 638
(18.2%) primary events occurred in pa-
tients assigned to aspirin therapy versus
117 of 638 (18.3%) in those on placebo
(HR 0.98, 95% CI 0.76–1.26). There
were 43 CHD or stroke deaths in the as-
pirin group and 35 in the placebo group
(6.7% vs. 5.5%; HR 1.23, 95% CI 0.79–
1.93). The rates of a wide variety of sec-
ondaryendpointsandadverseeventsalso
did not differ between groups. Outcomes
were also similar with or without the an-
tioxidants; there was no interaction be-
tween the two active therapies (10).
In JPAD, investigators examined the
efﬁcacy of low-dose aspirin for primary
prevention of cardiovascular events in a
randomized, open-label trial conducted
in 2,539 Japanese patients with type 2 di-
abetes but no history of CVD. Patients
were assigned to either aspirin (81–100
mgdaily)ornoaspirinandwerefollowed
for an average of 4.4 years. The primary
endpointwasacompositeoffatalornon-
fatal ischemic heart disease, fatal or non-
fatal stroke, and peripheral arterial
disease.Atotalof154eventsoccurred:68
(5.4%)intheaspiringroupand86(6.7%)
inthenonaspiringroup(HR0.80,95%CI
0.58–1.10). The combined secondary
end point of coronary and cerebrovascu-
lar mortality occurred in 1 patient
(stroke) in the aspirin group and 10 pa-
tients (ﬁve fatal MIs and ﬁve fatal strokes)
inthenonaspiringroup(HR0.10,95%CI
0.01–0.79). Other secondary end points
did not differ importantly between
groups. Overall, mortality occurred in 34
patients in the aspirin group and 38 pa-
tients in the nonaspirin group (HR 0.90,
95% CI 0.57–1.14). According to pre-
speciﬁed subgroup analyses, however, in
subjects over 65 years of age (n  1,363),
the incidence of the primary end point
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0.46–0.99) (9).
In summary, the currently available
evidence on aspirin for CVD prevention
includes three trials conducted speciﬁ-
cally in patients with diabetes and six
other trials in which patients with diabe-
tes constitutesubgroupswithinbroadertri-
als of aspirin prophylaxis. No single trial
provides deﬁnitive results. As such, we
sought, in question 2, to use meta-analysis
to try to reconcile the available data.
2. How can we reconcile the results
of the different trials?
In order to synthesize and reconcile the re-
sultsoftheavailabletrials,weexaminedex-
isting meta-analyses of aspirin prevention
trials (including those that focused on all
patients and those that examined only pa-
tients with diabetes) and performed new
meta-analyses with updated data.
The Anti-thrombotic Trialists’ (ATT)
collaborators recently published an indi-
vidual patient-level meta-analysis of the
six large trials of aspirin for primary pre-
vention in the general population (5).
These trials collectively enrolled over
95,000 participants, including almost
4,000 with diabetes. Overall, the meta-
analysis found that aspirin reduced the
risk of vascular events by 12% (RR 0.88,
95% CI 0.82–0.94). The largest reduc-
tionwasfornonfatalMI(RR0.77,95%CI
0.67–0.89). Aspirin had little effect on
CHDdeath(RR0.95,95%CI0.78–1.15)
or total stroke (RR 0.95, 95% CI 0.85–
1.06). The net effect on total stroke re-
ﬂected a relative reduction in risk of
ischemic stroke (14%) and a relative in-
creased risk of hemorrhagic stroke
(32%).
Therewassomeevidenceofadiffer-
ence in aspirin effect by sex. Aspirin re-
duced CHD events in men (RR 0.77,
95% CI 0.67–0.89) but not in women
(RR 0.95, 95% CI 0.77–1.17). Con-
versely, aspirin had no effect on stroke
in men (RR 1.01, 95% CI 0.74–1.39)
but reduced stroke in women (RR 0.77,
95% CI 0.59–0.99). These potential
differences in effect by sex were of bor-
derline statistical signiﬁcance, were af-
fectedstronglybytheresultsofonetrial
(WHS), and cannot be considered de-
ﬁnitive. Notably, sex differences in as-
pirin’s effects have not been observed in
studies of secondary prevention (5).
The ATT collaborators did not identify
other clear sources of heterogeneity of
effect, although there was some sugges-
tion that current smokers derived less
beneﬁt from aspirin than nonsmokers.
In the six trials examined by the ATT,
the effect of aspirin on major vascular
events was similar for patients with and
without diabetes: RR 0.88, 95% CI 0.67–
1.15, and RR 0.87, 95% CI 0.79–0.96,
respectively. The CI was wider for those
withdiabetesbecauseofthesmallernum-
berofparticipantswithdiabetesandtheir
smaller total numbers of CVD events.
We performed a new meta-analysis
that added data from three trials per-
formedspeciﬁcallyinpatientswithdiabe-
tes (JPAD, POPADAD, and ETDRS)
(9,10,18) to the data from the subgroups
ofpatientswithdiabetesfromthesixtrials
included in the ATT meta-analysis (Fig.
1). Using a random-effects model, we
found that aspirin was associated with a
9% decrease in risk of CHD events (non-
fatalandfatalMI)thatwasnotstatistically
Figure 1—Meta-analysis of trials examining the effects of aspirin on risk of CVD events in
patientswithdiabetes.A:EffectofaspirinonCHDevents.Testsforheterogeneity:
28.71,P
0.367, I
2  8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for hetero-
geneity:
211.0,P0.20,I
227.2%.BMD,BritishMedicalDoctors;CI,conﬁdenceinterval;
ETDRS,EarlyTreatmentofDiabeticRetinopathyStudy;HOT,HypertensionOptimalTreatment;
JPAD,JapanesePrimaryPreventionofAtherosclerosiswithAspirinforDiabetes;PHS,Physicians’
Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Pri-
mary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women’s Health Study.
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We did not identify important heteroge-
neity (
2  8.71, P  0.367, I
2  8.2%),
but a large portion of the summary esti-
mate depended on the ETDRS trial. Ex-
cluding this trial, the estimate of effect for
CHD events was smaller.
For stroke, our random-effects meta-
analysis of the nine trials found a reduc-
tion in the risk of stroke of 10% (RR 0.90,
95% CI 0.71–1.13) that was not statisti-
cally signiﬁcant. There was some hetero-
geneity (
2  11.0, P  0.20, I
2 
27.2%). The results of these diabetes-
speciﬁc analyses are consistent with the
ﬁndings of the ATT meta-analysis and
suggest that aspirin likely produces a
modest reduction in CVD risk, but limi-
tations in the amount of available data
preclude a precise estimate of effect. We
also do not have access to sufﬁcient pa-
tient-level data in patients with diabetes
to consider whether the effect of aspirin
on CHD events and stroke differs by sex,
the dose of aspirin used, or other clinical
factors.
Otherrecentmeta-analyseshaveexam-
ined the effect of aspirin on CVD events in
patients with diabetes. DeBerardis and col-
leagues (19) included six of the nine trials
included in our analysis (they did not in-
clude HOT, BMD, or TPT due to lack of
data on patients with diabetes in the orig-
inal publications) and found estimates of
effect with aspirin similar to those of our
analysis: for MI, RR 0.86 (95% CI 0.61–
1.21) with moderate heterogeneity (I
2 
62.2%), mainly due to inclusion of WHS
and PHS. For stroke, they included ﬁve
trials (excluding PHS) and calculated a
summary RR of 0.83 (95% CI 0.60–1.14)
and also noted moderate heterogeneity
(I
2  52.5%), mainly due to inclusion of
WHS.Theyalsoidentiﬁedpotentiallyim-
portant effect modiﬁcation by sex: aspirin
reduced MI for men (RR 0.57, 95% CI
0.34–0.94) but not for women (RR 1.08,
95% CI 0.71–1.65).
Zhang and colleagues (20) included
seven trials in their meta-analysis (they
did not include BMD or TPT) and also
found similar results (for MI, RR 0.85,
95% CI 0.65–1.11; for stroke, RR 0.83,
95% CI 0.63–1.10). They performed
meta-regression and identiﬁed important
differences in outcomes by sex. They
found no evidence of publication bias
based on funnel plots using Begg and
Eggertests.Calvinandcolleagues(21)in-
cluded seven trials from our meta-
analysis of patients with diabetes (they
did not include TPT or BMD) and for MI
found RR 0.86 (95% CI 0.67–1.11) using
the seven trials. For ischemic stroke, they
found RR 0.62 (95% CI 0.31–1.24) using
only the results of WHS and JPAD for
their analysis.
The trials pooled in all of the meta-
analyses varied widely in the CHD event
ratesinthecontrolgroup.IftheRRreduc-
tion (the metric being pooled) is con-
sistent across patients of differing under-
lying absolute risk, as suggested by
secondary prevention trials and the indi-
vidual patient-level meta-analysis (5),
then such analyses seem to be reasonable.
Taken together, the other meta-analyses
reinforce our main ﬁndings: aspirin ap-
pears to produce a modest-sized reduc-
tion in MI and stroke in patients with
diabetes, but current evidence is not con-
clusive because there have been too few
events in the available trials to precisely
estimate its effects and because our ﬁnd-
ings rely on analyses of subgroups within
larger trials, which have more potential
for bias. The currently available data also
reinforce that the possible differences in
outcomes for men and women require
further study.
3. What are the potential harms of
aspirin, and are these similar or
different for people with diabetes
compared to those without?
The major adverse effects of aspirin ther-
apyincludeintracranialbleeding(hemor-
rhagic stroke) and extracranial bleeding,
principallygastrointestinal.Basedondata
from primary and secondary prevention
trials conducted in mixed populations of
patients with and without diabetes, low-
doseaspirinappearstobeassociatedwith
an absolute risk of hemorrhagic stroke of
1in10,000peopleannually(22).Anal-
yses that examined the primary preven-
tion trials separately have reached similar
results (5,23). These hemorrhagic strokes
are incorporated in the estimate of the ef-
fect of aspirin on all strokes considered
above in question 2.
For extracranial (mainly gastrointes-
tinal) bleeding, aspirin use is associated
with a 54% increase in risk based on
meta-analysis of the six primary preven-
tion trials (RR 1.54, 95% CI 1.30–1.82).
The absolute increase in risk was on the
order of 3 in 10,000 per year in mainly
middle-agedadultsenrolledintheaspirin
primary prevention trials. The ATT col-
laboration authors found that several risk
factors for CVD also increased the risk for
extracranial bleeding from aspirin, sug-
gesting that those at higher CVD risk are
also at higher risk for aspirin-related ad-
verse effects. Those with diabetes taking
aspirin experienced a 55% increased risk
(RR 1.55, 95% CI 1.13–2.14) compared
with those without diabetes (5). Since the
primarypreventiontrialsusedbytheATT
collaboration and by this meta-analysis
excluded patients with a history of peptic
ulcer disease, the risk calculations for
bleeding cannot be extended to that
population.
Notably, the absolute excess risk of
gastrointestinal bleeding with aspirin is
likely higher among free-living older
adults, with rates of 1–10 per 1,000 an-
nually reported in a large cohort study
(24). While evidence supports that use of
proton-pump inhibitors (PPIs) can de-
creasetheriskofrecurrentaspirin-related
gastrointestinal bleeding (25), it is not
clear whether routine use of a PPI is cost-
effective or should be recommended for
primary prevention of gastrointestinal
bleeding.
4. What do we know about the
recommended dosage or dosage
range?
The optimal dosage of aspirin for preven-
tionofcardiovasculareventsisnotclearly
established from the outcomes literature.
The average daily dose used in the pri-
mary prevention trials involving partici-
pants with diabetes ranged from 50 to
650 mg daily (Table 1). Indirect evidence
from the ATT collaboration suggests that
the risk reductions achieved with low
doses (75–162 mg/day) are as large as
those obtained with higher doses (500–
1,500 mg/day) and larger than those in
the few trials that have used doses below
75 mg/day (26). The failure of higher
doses to produce greater reductions in
thrombotic events may in part be due to
the fact that the inhibitory effects of aspi-
rin on the platelet are permanent. Thus,
even low doses will achieve a full effect
after several days of dosing. Additionally,
the effects of aspirin begin in the portal
circulation and are thereby presystemic.
This removes the variability of hepatic
metabolism, which accounts for much of
the pharmacodynamic variability with
other agents such as clopidogrel (27,28).
Although platelets from patients with
diabetes have altered function, it is un-
clear what, if any, impact that ﬁnding has
ontherequireddoseofaspirinforcardio-
protective outcomes in the diabetic pa-
tient (29). Many alternate pathways exist
for platelet activation and aggregation
(adenosine diphosphate, thrombin, epi-
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independentofthromboxaneA2andthus
not sensitive to the effects of aspirin (30).
Therefore, while aspirin resistance ap-
pearshigherinthediabeticpatientswhen
measured by a variety of ex vivo and in
vitro methods (platelet aggregometry,
measurement of thromboxane B2), these
observations alone are insufﬁcient to em-
pirically recommend higher doses of as-
pirinbeusedinthediabeticpatientatthis
time (31–33).
5. How can we integrate potential
beneﬁts and harms of aspirin to
determine which patients with
diabetes should or should not
receive aspirin for the primary
prevention of CV events?
Basedonthecurrentlyavailableevidence,
aspirin appears to have a modest effect on
cardiovascular events (RR reduction of
10%), with the absolute decrease in
events depending on the underlying CVD
risk (those with higher baseline risk
shouldhavegreaterabsolutebeneﬁt).The
main adverse effects appear to be an in-
creased risk of gastrointestinal bleeding.
The excess risk may be as high as 1–5 per
1,000 per year in real-world settings. In
adults with CVD risk greater than 1% per
year, the number of CVD events pre-
vented will be similar to or greater than
the number of bleeding events induced,
although the events considered (MI,
stroke, and gastrointestinal bleeding) do
nothaveequaleffectsonlong-termhealth
(34). We have developed recommenda-
tions based on these data.
The effect of aspirin for primary pre-
vention of CVD events in adults with di-
abetes is currently unclear. Trials to date
have reached mixed results, but overall
suggestthataspirinmodestlyreducesrisk
of cardiovascular events. More research is
needed to better deﬁne the speciﬁc effects
of aspirin in diabetes, including any sex-
speciﬁc differences. For now, we recom-
mend the following:
● Low-dose (75–162 mg/day) aspirin use
for prevention is reasonable for adults
with diabetes and no previous history
of vascular disease who are at increased
CVD risk (10 year risk of CVD events
over10%)andwhoarenotatincreased
risk for bleeding (based on a history of
previous gastrointestinal bleeding or
peptic ulcer disease or concurrent use
of other medications that increase
bleeding risk, such as NSAIDS or war-
farin). Those adults with diabetes at in-
creased CVD risk include most men
over age 50 years and women over age
60 years who have one or more of the
following additional major risk factors:
smoking, hypertension, dyslipidemia,
family history of premature CVD, and
albuminuria. (ACCF/AHA Class IIa,
Level of Evidence B) (ADA Level of Ev-
idence C)
● Aspirin should not be recommended
for CVD prevention for adults with di-
abetes at low CVD risk (men under age
50 years and women under 60 years
with no major additional CVD risk fac-
tors;10-yearCVDriskunder5%)asthe
potential adverse effects from bleeding
offset the potential beneﬁts. (ACCF/
AHA Class III, Level of Evidence C)
(ADA Level of Evidence C)
● Low-dose (75–162 mg/day) aspirin use
for prevention might be considered for
those with diabetes at intermediate
CVD risk (younger patients with one or
moreriskfactors,orolderpatientswith
no risk factors, or patients with 10-year
CVD risk of 5–10%) until further re-
search is available. (ACCF/AHA Class
IIb, Level of Evidence C) (ADA Level of
Evidence E)
Cardiovascularriskassessment. These
recommendations depend on the accu-
rate assessment of cardiovascular risk as
partofthedecision-makingprocessabout
aspirin use. All patients with diabetes do
not have high cardiovascular risk, despite
the assumptions of some previous guide-
lines (35). We have provided treatment
guidance based on either a combination
of age, sex, and other risk factors or on an
estimate of absolute cardiovascular risk.
An important consideration is that pa-
tients may acquire additional risk factors
over time, which would necessitate a re-
assessment of their overall risk proﬁle.
The absolute risk-based recommenda-
tions require the use of a risk prediction
tool. Tools that can be used in patients
with diabetes are available from several
sources, for example:
UKPDS Risk Engine: http://www.dtu.
ox.ac.uk/riskengine/index.php
ARIC CHD Risk Calculator: http://
www.aricnews.net/riskcalc/html/RC1.
html
American Diabetes Association Risk As-
sessment Tool, Diabetes PHD: http://
www.diabetes.org/phd
Concurrent therapies. Whether pa-
tients have sufﬁcient CVD risk to warrant
aspirin use under these assumptions will
also depend on the use of other effective
techniques for CVD risk reduction, in-
cluding statins, blood pressure control,
and smoking cessation (36,37). Each of
these therapies also lowers the risk of
CVD events and should be considered
when deciding about aspirin use. If these
other effective treatments are adopted
ﬁrst, then fewer patients with diabetes
will remain at sufﬁcient risk to warrant
aspirinuse,inlightofitspotentialadverse
effects. For example, a patient at 20% 10-
yearriskbasedonelevatedbloodpressure
and suboptimal lipid levels would have
hisriskreducedfrom20to13%bytaking
a statin and from 13 to 10% based on
effective blood pressure control, which
makes the decision about whether to take
aspirin more complex. Although the risk
reduction with these additional therapies
does not occur immediately, their effects
can be assumed to occur with rapidity
sufﬁcient to incorporate them in the ini-
tial decision-making process.
6. What are the needs for future
research?
Two ongoing studies will provide addi-
tionalinformationontheroleoflow-dose
aspirin for the prevention of cardiovascu-
lar events speciﬁcally in patients with
diabetes.AspirinandSimvastatinCombi-
nation for Cardiovascular Events Preven-
tion Trial in Diabetes (ACCEPT-D) is an
open-label Italian primary prevention
trialcomparingaspirin100mgdailytono
aspirin among adults over age 50 years
with diabetes who are also taking simva-
statin (38). The planned enrollment is
5,170, and the investigators will examine
several prespeciﬁed subgroups to detect
differences in effect of aspirin, including
men versus women and older versus
younger age, as well as baseline lipid lev-
els and use of statins. A second trial, A
Study of Cardiovascular Events in Diabe-
tes (ASCEND), is being conducted in the
U.K. and will also examine the effects of
100 mg aspirin daily versus placebo
amongmenandwomenoverage40years
who have either type 1 or type 2 diabetes
but no previous vascular events (39). It
uses a double-blind placebo-controlled
and 2  2 factorial design that will also
examine the effects of 	-3 fatty acid sup-
plements. The planned enrollment is
10,000, which was designed to provide
adequate power to detect a 20% reduc-
tion in major vascular events including
both MI and stroke.
Although these trials will provide im-
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sible that they will not deﬁnitively
determine whether aspirin is effective for
prevention of CHD events in people with
diabetes. This may be especially true for
important subgroups such as patients on
statins, women, and patients with type 1
diabetes. Although ASCEND is powered
for a 20% RR reduction, an RR reduction
of 10% among patients with an underly-
ingincidenceof10%inthecontrolgroup
would require over 36,000 participants if
90%powerisdesiredand26,000for80%
power. To achieve this event rate among
moderate-risk patients with diabetes (an-
nual event rates of 1–2%), a trial would
need to be 5–10 years in duration. Thus,
while the ongoing trials may not provide
deﬁnitiveanswers,theircombinedenroll-
ment of over 15,000 patients will add im-
portant new information on the role of
aspirin for primary prevention in patients
with diabetes.
In addition, development of reliable
surrogatetestingforplateletreactivityand
response to antiplatelet therapies would
be helpful in the management of patients
for whom concerns have been raised
about aspirin resistance, such as those
with diabetes (27,28). Such testing could
also allow more precise determination of
the dose-response relationship for aspirin
in patients both with and without diabe-
tes and better inform the design of large
outcomes studies. However, while some
encouraging epidemiologic and retro-
spective data exists for current methods
of surrogate platelet testing for aspirin,
these data lack sufﬁcient rigor to inform
clinical decision making, particularly
in the setting of primary prevention
(32,33,40).
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